- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04052776
Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES (STIMO-PHARMA)
Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With Spinal Cord Injury Treated With Epidural Electrical Stimulation
In a current first-in-man study, called Stimulation Movement Overground (STIMO) (NCT02936453; CER-VD: 04-2014; Swissmedic: 2016-MD-0002), epidural electrical stimulation (EES) of the spinal cord is applied to enable individuals with severe spinal cord injury (SCI) to complete intensive locomotor neurorehabilitation training. In this clinical feasibility study, it was demonstrated that EES results in an immediate enhancement of locomotor functions and that when applied repeatedly as part of a neurorehabilitation program, EES can progressively improve leg motor control in individuals with severe SCI. Mechanistically, EES acts trans-synaptically upon spinal circuitries through the electrical stimulation of proprioceptive fibers.
It is assumed that this stimulation does not increase the level of availability of monoamine neurotransmitters below the SCI level, which are essential for lower extremity movement generation. Specifically, in a non-injured individual, dopamine and serotonin synthesized in the brain and brainstem are released by fibers diffusely innervating the spinal cord, serving to critically mediate excitability of motor neurons and interneurons in lumbar and sacral spinal level. Spinal cord injury would partially or entirely disrupt these modulation pathways, resulting in a detrimental lack of crucial neurotransmitters below the injury level. This lack of endogenous neurotransmitters could potentially be compensated for by pharmacological agents promoting the neurochemical environment necessary for locomotion.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim is to test the effects of orally administered buspirone and levodopa/carbidopa taken individually and in combination. Both buspirone and levodopa can cross the blood-brain barrier, and reach the lumbar spinal cord where 5-HT1A receptors are expressed, and levodopa can presumably be synthesized by specialized dopaminergic into dopamine. Alternatively, levodopa effects might be mediated via noradrenaline, following dopamine metabolization. Therefore, it is hypothesized that the combination of pharmacological neuromodulation with EES would further improve locomotor functions and lower extremity motor score.
The primary and safety objective is to evaluate the safety and the tolerability of a single-dose of immediate-release levodopa/carbidopa, buspirone, the combination levodopa/carbidopa and buspirone, and the placebo in individuals with SCI.
The secondary objectives are to assess the following effects of levodopa/carbidopa, buspirone, the combination levodopa/carbidopa and buspirone, and the placebo on the lower extremities:
- Spasticity
- Lower Extremity Motor score (LEMS)
- Voluntary movements
- Gait patterns and velocity Participants' safety will be ensured with the usage of Rysen, which a CE-marked bodyweight support system robot, and the aid of locomotor assistive device.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Vaud
-
Lausanne, Vaud, Switzerland, 1011
- CHUV
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Completed the main phase of the STIMO study
- Enrolled in the STIMO study extension
- Age 18-65 (women or men)
- Sensorimotor or motor complete and incomplete SCI graded as AIS A, B, C & D
- Stable medical, physical and psychological condition as considered by Investigators
- Able to understand and interact with the study team in French or English
- Adequate caregiver support and access to appropriate medical care in the patient's home community
- Agree to comply with all conditions of the study and to attend all required study training and visit
- Must provide and sign Informed Consent prior to any study-related procedures
Exclusion Criteria:
- Epilepsy
- Women who are pregnant (pregnancy test obligatory for women of childbearing potential) or breastfeeding or not willing to take contraception.
- Known or suspected non-compliance, drug or alcohol abuse.
- Gastrointestinal ulcers in the last five years
- Known or suspected eye disorders or diseases
- Known or suspected allergies or hypersensitivity to buspirone, levodopa or carbidopa.
Taking selective and non-selective serotonin reuptake inhibitors or any other treatments acting upon serotonergic transmission, such as the following:
- Selective serotonin reuptake inhibitors (SSRIs)
- Serotonin-norepinephrine reuptake inhibitors (SNRIs)
- Serotonin antagonists and reuptake inhibitors (SARIs)
- Tricyclic antidepressants (TCAs)
- Tetracyclic antidepressants (TeCAs)
- Norepinephrine-dopamine reuptake inhibitors (NDRIs)
- Monoamine oxidase inhibitors (MAOIs)
- Patients who are receiving treatments altering the noradrenergic and dopaminergic transmission (e.g., bupropion and levodopa/carbidopa)
- Patients who are taking narcotic pain killers (e.g., opioids) and neuropathic medication (e.g., gabapentin, pregabalin)
- Patients who are taking antihypertensive drugs and diuretics (e.g., furosemide or hydrochlorothiazide)
- Patients who are taking hypnotic drugs (e.g., Zolpidem).
- Patients receiving D2 antagonists or antipsychotic drugs (e.g., butyrophenone, phenothiazines, risperidone)
- Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Buspirone
40mg
|
40mg
|
Active Comparator: Levodopa-Carbidopa
400mg/100mg
|
400mg/100mg
|
Active Comparator: Buspirone + Levodopa-Carbidopa
40mg + 400mg/100mg
|
40mg + 400mg/100mg
|
Placebo Comparator: Placebo
Mannitol pill
|
Non-active metabolite
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of AEs/SAEs/Side effects
Time Frame: Changes from baseline condition over a treatment session of 4 hours
|
Evaluate the safety of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo.
|
Changes from baseline condition over a treatment session of 4 hours
|
Changes in blood pressure
Time Frame: Changes from baseline condition over a treatment session of 4 hours
|
Evaluate the safety of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo -Vitals signs will be monitored throughout the treatment session to evaluate the fluctuations from baseline condition. |
Changes from baseline condition over a treatment session of 4 hours
|
Changes in heart rate
Time Frame: Changes from baseline condition over a treatment session of 4 hours
|
Evaluate the safety of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo -Vitals signs will be monitored throughout the treatment session to evaluate the fluctuations from baseline condition. |
Changes from baseline condition over a treatment session of 4 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Spasticity of the Lower Extremities (score according to the Pendulum test)
Time Frame: Changes from baseline condition over a treatment session of 4 hours
|
Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo. -Assessment of the lower extremities' spasticity. |
Changes from baseline condition over a treatment session of 4 hours
|
Lower Extremity Motor Strength (M0-M5 score according to the AIS)
Time Frame: Changes from baseline condition over a treatment session of 4 hours
|
Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo. -Assessment of the lower extremities' motor strength by a clinician. |
Changes from baseline condition over a treatment session of 4 hours
|
Lower Extremity Motor Strength (muscle activity)
Time Frame: Changes from baseline condition over a treatment session of 4 hours
|
Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo. -Assessment of the lower extremities' motor strength by EMGs. |
Changes from baseline condition over a treatment session of 4 hours
|
Lower Extremity Voluntary Movements (kinematics assessment through VICON)
Time Frame: Changes from baseline condition over a treatment session of 4 hours
|
Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo. -Participants' voluntary movements will be assessed by kinematics analyses through the VICON) |
Changes from baseline condition over a treatment session of 4 hours
|
Lower Extremity Voluntary Movements (muscle activity)
Time Frame: Changes from baseline condition over a treatment session of 4 hours
|
Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo. -Participants' muscles during the voluntary movements will be assessed by EMGs. |
Changes from baseline condition over a treatment session of 4 hours
|
Walking speed (10MWT)
Time Frame: Changes from baseline condition over a treatment session of 4 hours
|
Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo. -Participants' velocity will be assessed with a 10MWT with and without EES |
Changes from baseline condition over a treatment session of 4 hours
|
Gait pattern (kinematics assessment through VICON)
Time Frame: Changes from baseline condition over a treatment session of 4 hours
|
Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo. -Participants' gait pattern during a 10MWT will be assessed by kinematics analyses through the VICON |
Changes from baseline condition over a treatment session of 4 hours
|
Gait pattern (muscle activity)
Time Frame: Changes from baseline condition over a treatment session of 4 hours
|
Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo. -Participants' muscle activity will be assessed during a 10MWT with EMGs. |
Changes from baseline condition over a treatment session of 4 hours
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jocelyne Bloch, Pr MD, CHUV
Publications and helpful links
General Publications
- Wagner FB, Mignardot JB, Le Goff-Mignardot CG, Demesmaeker R, Komi S, Capogrosso M, Rowald A, Seanez I, Caban M, Pirondini E, Vat M, McCracken LA, Heimgartner R, Fodor I, Watrin A, Seguin P, Paoles E, Van Den Keybus K, Eberle G, Schurch B, Pralong E, Becce F, Prior J, Buse N, Buschman R, Neufeld E, Kuster N, Carda S, von Zitzewitz J, Delattre V, Denison T, Lambert H, Minassian K, Bloch J, Courtine G. Targeted neurotechnology restores walking in humans with spinal cord injury. Nature. 2018 Nov;563(7729):65-71. doi: 10.1038/s41586-018-0649-2. Epub 2018 Oct 31.
- Formento E, Minassian K, Wagner F, Mignardot JB, Le Goff-Mignardot CG, Rowald A, Bloch J, Micera S, Capogrosso M, Courtine G. Electrical spinal cord stimulation must preserve proprioception to enable locomotion in humans with spinal cord injury. Nat Neurosci. 2018 Dec;21(12):1728-1741. doi: 10.1038/s41593-018-0262-6. Epub 2018 Oct 31.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Wounds and Injuries
- Trauma, Nervous System
- Spinal Cord Diseases
- Spinal Cord Injuries
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Immunologic Factors
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Dopamine Agonists
- Dopamine Agents
- Serotonin Receptor Agonists
- Anti-Anxiety Agents
- Adjuvants, Immunologic
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Aromatic Amino Acid Decarboxylase Inhibitors
- Buspirone
- Levodopa
- Carbidopa
- Carbidopa, levodopa drug combination
Other Study ID Numbers
- 2019-01057
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Effect
-
Walter Reed National Military Medical CenterUnited States Department of Defense; General Services Administration (GSA)Active, not recruitingAdverse Drug Effect of Opioids | Adverse Drug Effect of BenzodiazepinesUnited States
-
Oslo University HospitalRecruiting
-
Boston Children's HospitalRecruiting
-
Boston Children's HospitalTerminatedDrug EffectUnited States
-
Suez Canal UniversityCompleted
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)Completed
-
Services Institute of Medical Sciences, PakistanUnknown
-
Boston Children's HospitalRecruitingDrug EffectUnited States
-
Tanta UniversityCompleted
Clinical Trials on Buspirone
-
Johns Hopkins Bloomberg School of Public HealthJohns Hopkins University; Massachusetts General Hospital; National Institute... and other collaboratorsCompleted
-
Massachusetts General HospitalBrainCells Inc.CompletedMajor Depressive DisorderUnited States
-
Beijing Union Pharmaceutical Factory LtdR&G Pharma Studies Co.,Ltd.RecruitingGeneralized Anxiety DisorderChina
-
Spaulding Rehabilitation HospitalRecruitingSpinal Cord InjuriesUnited States
-
Par Pharmaceutical, Inc.Phoenix International Life Sciences, Inc.CompletedTo Determine Bioequivalence Under Fed ConditionsCanada
-
Par Pharmaceutical, Inc.Phoenix International Life Sciences, Inc.CompletedTo Determine Bioequivalence Under Fasting ConditionsCanada
-
Laikο General Hospital, AthensCompleted
-
University of OxfordCompleted
-
Nordic Life Science Pipeline Inc.United States Department of DefenseCompleted
-
Northwestern UniversityNational Alliance for Research on Schizophrenia and DepressionCompletedSchizophrenia | Schizoaffective DisorderUnited States